Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$73.30 USD

73.30
7,101,316

+1.66 (2.32%)

Updated Jul 17, 2024 04:00 PM ET

After-Market: $73.34 +0.04 (0.05%) 6:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

AstraZeneca (AZN) Gets EU Nod & CHMP Opinions for Some Drugs

The CHMP recommends approvals for expanded use of AstraZeneca's (AZN) Enhertu in breast cancer, Imfinzi plus Imjudo in lung and liver cancers and Forxiga in heart failure.

Roche's (RHHBY) Hemophilia A Drug Gets Positive CHMP Opinion

Roche (RHHBY) receives a positive CHMP recommendation for label expansion of the hemophilia A drug Hemlibra in the European Union (EU).

AbbVie (ABBV) Vraylar Gets FDA Nod for Major Depressive Disorder

FDA approves AbbVie's (ABBV) Vraylar (cariprazine) for its fourth indication - the adjunctive treatment of patients with MDD.

BioCryst (BCRX) Down as it Discontinues Developing PNH Drug

BioCryst (BCRX) down as it drops the development of BCX9930, which was being evaluated for PNH.

Cytokinetics (CYTK) Up Despite Unfavorable FDA Committee Voting

Cytokinetics (CYTK) gets an unfavorable recommendation from CRDAC on omecamtiv mecarbil for the treatment of heart failure with reduced ejection fraction.

Rajani Lohia headshot

Top 5 High-Yield S&P 500 Stocks to Buy for 2023

With risks of elevated inflation, rising interest rates and geopolitical turmoil, investments in high-yield dividend stocks offer a defensive play. Stocks like GILD, CAG, CAT, CFG and NRG look attractive.

Gilead Sciences (GILD) Stock Moves -0.39%: What You Should Know

Gilead Sciences (GILD) closed at $88.40 in the latest trading session, marking a -0.39% move from the prior day.

Biotech Stock Roundup: HZNP Surges on AMGN Offer, TRDA Gains on VRTX Deal & More

Acquisitions news from HZNP and AMGN form the key highlights from the biotech sector during the past week.

bluebird (BLUE) Up on Positive Data on Gene Therapies at ASH

bluebird (BLUE) gains on positive data on Zyntgelo in beta-thalassemia and lovo-cel in sickle cell disease.

Gilead (GILD) Partners With Arcellx, ImmunoGen in Oncology

Gilead (GILD) announces deals with Arcellx, Inc. and ImmunoGen to strengthen its oncology pipeline.

Sumit Singh headshot

4 Stocks With Impressive Interest Coverage Ratio to Snap Up

A company that is capable of generating earnings well above its interest expense can withstand financial hardship. Sprouts Farmers (SFM), Fortinet (FTNT), O'Reilly Automotive (ORLY) and Gilead Sciences (GILD) are strong enough to meet financial obligations.

Entrada (TRDA) Surges on Collaboration With Vertex for DMI

Entrada (TRDA) gains from its collaboration deal with Vertex to discover and develop Endosomal Escape Vehicle (EEV) therapeutics for DM1.

Kodiak Sciences Inc. (KOD) Up 1% Since Last Earnings Report: Can It Continue?

Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Smart Beta ETF report for PJP

Esperion (ESPR) Reports Positive Data From CLEAR Study

Esperion (ESPR) announces positive data from the CLEAR Outcomes study, which further strengthens the clinical evidence supporting the role of bempedoic acid for patients and will boost the growth potential of the drug.

Biogen (BIIB), Sage Finish Zuranolone NDA Filing for Depression

Biogen (BIIB) and Sage Therapeutics (SAGE) NDA submission for zuranolone for treating MDD and PPD is based on data from two late-stage studies, LANDSCAPE and NEST.

Wall Street Bulls Look Optimistic About Gilead (GILD): Should You Buy?

The average brokerage recommendation (ABR) for Gilead (GILD) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

The Zacks Analyst Blog Highlights Exxon Mobil, WesBanco, S&T Bancorp, Gilead Sciences and Conagra Brands

Exxon Mobil, WesBanco, S&T Bancorp, Gilead Sciences and Conagra Brands are included in this Analyst Blog.

Biogen's (BIIB) ALS Drug Tofersen Filing Accepted in Europe

Biogen's (BIIB) tofersen, if approved, will be the first genetically-targeted treatment for SOD1-ALS in Europe.

Tirthankar Chakraborty headshot

5 Dividend Stocks to Allay Fears of a More-Aggressive Fed

As U.S. stocks stumble on concerns of further rate hikes, investing in dividend players like Exxon Mobil (XOM), Gilead Sciences (GILD) and Conagra Brands (CAG) for a steady stream of income seems prudent.

GSK's Myelofibrosis Candidate MAA Gets Accepted in Europe

GSK's new drug application (NDA) for momelotinib is under standard FDA review, with a decision expected on Jun 16, 2023.

Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?

Here is how Gilead Sciences (GILD) and HealthEquity (HQY) have performed compared to their sector so far this year.

Allogene Therapeutics (ALLO) Down 1.6% Since Last Earnings Report: Can It Rebound?

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Roivant (ROIV), Pfizer Form Vant for Inflammatory Disease Drug

Roivant Sciences (ROIV), Pfizer's (PFE) new Vant company will take care of funding the global development of RVT-3101 in inflammatory and fibrotic diseases.

Why Is Exelixis (EXEL) Up 0.4% Since Last Earnings Report?

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.